Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO to Present at 10th Annual CNS Summit 2019

30 Oct 2019 09:00

RNS Number : 5364R
IXICO plc
30 October 2019
 

30 October 2019

 

IXICO plc

("IXICO" or the "Company")

 

IXICO to Present at 10th Annual CNS Summit 2019

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit 

31st October - 3rd November 2019, Boca Raton Resort, Florida, USA

 

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs. 

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

 

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

 

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus

 

IXICO@optimumcomms.com

 

 

About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

About CNS Summit

 

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABRBDGXXDBGCC
Date   Source Headline
16th Jan 20172:00 pmRNSAnnual Report and Accounts and Notice of AGM
13th Jan 20173:25 pmRNSHolding(s) in Company
12th Jan 20172:56 pmRNSHolding(s) in Company
4th Jan 20173:43 pmRNSIssue of 590,093 Deferred Consideration Shares
23rd Dec 20167:00 amRNSBuyback and Cancellation of Deferred Shares
20th Dec 20167:00 amRNSFull Year Results
16th Nov 20167:00 amRNSParticipation in major EU partnership (ROADMAP)
21st Oct 20167:00 amRNSPre-Close Trading Update
20th Oct 20167:00 amRNS$1.2m contract with new global pharma customer
19th Oct 20167:00 amRNSIXICO presents at CAMD regulatory workshop
10th Oct 20167:00 amRNSEUR1m funding as a partner in major EU consortium
3rd Oct 20167:00 amRNSAppointment of Shore Capital as Nominated Adviser
3rd Oct 20167:00 amRNSAppointment of Shore Capital
26th Sep 20165:14 pmRNSDirector/PDMR Shareholding
26th Sep 20161:58 pmRNSExercise of Share Options
16th Sep 20167:00 amRNSBoard changes
13th Sep 20167:00 amRNSPresentation of Assessa® PML at ECTRIMS
29th Jul 201610:25 amRNSWeb-Based Technology Improves Paediatric ADHD Care
7th Jun 20167:00 amRNSHalf Yearly Report to 31 March 2016
2nd Jun 20167:00 amRNSCygnus joins Dementias Platform UK
4th Apr 20167:00 amRNSConsortium and Five Year Contract
31st Mar 20167:00 amRNSReal world study of Digital Biomarkers
31st Mar 20167:00 amRNSGrant of Awards to Directors
30th Mar 20167:00 amRNSNHS emergency and out-of-hours services contract
9th Mar 20169:30 amRNSEuropean research to tackle dementia
3rd Mar 20167:00 amRNSMehealth® used in American Academy of Pediatrics
1st Mar 201610:35 amRNSDirector/PDMR Shareholding
5th Feb 20167:00 amRNSDirector/PDMR Shareholding
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
29th Jan 201610:45 amRNSResult of AGM
29th Jan 20167:00 amRNSAGM Statement
22nd Jan 20167:00 amRNSSelected for two NHS Innovation Test Beds
21st Jan 20167:00 amRNSMyBrainBook wins Regional Business Award
18th Jan 20167:00 amRNSFour contracts awarded worth over £3.0m
7th Jan 20167:00 amRNSFinancial Results for the year ended 30 Sept 2015
21st Dec 20152:03 pmRNSUpdate on Issued Share Capital
7th Dec 201510:04 amRNSResult of General Meeting
18th Nov 20153:45 pmRNSPublication of Circular
18th Nov 20157:00 amRNSProposed acquisition of Optimal Medicine & placing
2nd Nov 20153:38 pmRNSTotal Voting Rights
19th Oct 20157:00 amRNSPre-Close Trading Update
12th Oct 20151:16 pmRNSAdditional Listing
9th Oct 20157:00 amRNSCollaboration with leading pharmaceutical co in MS
2nd Oct 201511:18 amRNSExercise of Share Options
28th Aug 20157:00 amRNSIXICO awarded significant long-term contract
29th Jun 20157:00 amRNSVirtualScopics Alliance Update
25th Jun 20151:21 pmRNSHolding(s) in Company
26th May 20157:01 amRNSRelease of beta version of MyBrainBook®
12th May 20157:00 amRNSLaunch of UK Government funded project
30th Apr 20157:49 amRNSLaunch of dementia care digital platform

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.